Notes

Announcement of Xiamen jindawei Group Co., Ltd. and Jiangsu Chengxin Pharmaceutical Co., Ltd. on purchasing 86% shares
NMN (Nicotinamide Mononucleotide),

Securities abbreviation: 002626 securities code: jindawei Announcement No. 2020-070
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Special note:
1. On December 1, 2020, the 15th meeting of the seventh board of directors of Xiamen jindawei Group Co., Ltd. (hereinafter referred to as "the company" or "jindawei") deliberated and adopted the proposal on purchasing 86% equity of Jiangsu Chengxin Pharmaceutical Co., Ltd., and decided that the company would subscribe 86% shares of Jiangsu Chengxin Pharmaceutical Co., Ltd. with its own capital of 307.3 million yuan.
2. 60.85% of the shares of Jiangsu Chengxin Pharmaceutical Co., Ltd. are pledged, which has the risk of lifting the mortgage barrier and causing losses to the company due to the failure of transaction.
3) in addition, there may also be evaluation risk, profit fluctuation risk, investment loss risk caused by potential litigation, business risk and business integration risk, impairment risk, transaction failure risk caused by the buyer and the seller's failure to perform the contract and other factors.
The company invites investors to pay special attention to the above risk tips, and the company will timely perform the obligation of information disclosure according to the transaction progress.
1、 Transaction summary
（1） In order to speed up the development of the enterprise and promote mutual benefit and win-win, jindawei, the natural person, Bian Yuhua, and the investment agreement on Jiangsu Chengxin Pharmaceutical Co., Ltd. (hereinafter referred to as the "agreement") and Anhui Fengyuan Pharmaceutical Co., Ltd. (hereinafter referred to as "Fengyuan pharmaceutical" (Nanjing Guanjun investment cooperation enterprise) and "Guanjun" . the natural person Yan Yu) signed the investment agreement on the equity transfer agreement of Jiangsu Chengxin Pharmaceutical Co., Ltd., and jindawei has its own funds of 307.3 million
（2） In this stock transaction, the company hired Fujian Lixin law firm and Lixin Certified Public Accountants (special general partnership) from an independent third-party intermediary to conduct legal and financial due diligence, appraisal and asset evaluation on Chengxin pharmaceutical, and the legal due diligence report on Jiangsu Chengxin Pharmaceutical Co., Ltd. and its affiliated enterprises Pieces, 33600 pieces.
（3） The 15th meeting of the 7th board of directors was held on December 1, 2020, and adopted 33.36 million-30000 by 9 votes in favor, 0 against and 0 abstention. According to 33, 360, 010-30, 000, 33, 360, 010-30, 000 and other relevant regulations, the purchase of shares is the decision authority of the board of directors and does not need to be submitted to the general meeting of shareholders.
Website: https://www.esthelivsale.com/wholesale